Several days ago, the EHC received a statement from Novo Nordisk concerning manufacturing issues related to NovoSeven, NovoEight, and Esperoct.

On 25 March 2025, the EHC held a Round Table discussion titled ‘Advancing Women’s Health – The Importance of Early Diagnosis for Women with Bleeding Disorders’ at the European Parliament in Brussels, hosted by MEP Stine Bosse.

On World Oral Health Day, the EHC teams up with Professor Alison Dougall to emphasise the importance of good oral hygiene as a key step in preventing complex and invasive dental procedures for people with bleeding disorders.

The European Commission unveiled the Critical Medicines Act aimed at strengthening the resilience of Europe’s pharmaceutical supply chains and ensuring equitable access to essential medicines. The EHC believes it is essential that the voices of patients with rare diseases are heard.

In the aftermath of Pfizer’s decision to halt the global commercialisation of fidanacogene elaparvovec-dzkt, the EHC urges pharmaceutical companies, health authorities, and stakeholders to remain committed to advancing treatment options for haemophilia and other bleeding disorders.

This publication is entirely developed by the EHC to inform its National Member Organisations about the rapidly changing landscape of health policy and legislative developments which have a direct impact on the bleeding disorders community.